Onyx’s Kyprolis RECEIVES FDA Approval and 4 Stock Analyses Making Headlines

BrainStorm Cell Therapeutics (BCLI) announced the completion of the planned interim safety review of its Phase I/II ALS, or Amyotrophic Lateral Sclerosis, clinical trial, which indicates that autologous transplantation of the company’s cell therapy was tolerated well, seems to be safe for use, and did not show any undue risks to the participants of the study. Also, the company reports that in some patients the pilot study showed a tendency toward stabilization in a few parameters in the ALS Functioning Rating Scale. The company has submitted the positive interim safety report to the Israeli Ministry of Health. The interim data was reported for the first group of patients, which all suffer from the early stages of ALS, or Lou Gehrig’s disease. All patients who were enrolled were transplanted with NurOwn either intramuscularly or intrathecally. The U.S. FDA has granted Orphan-drug designation for NurOwn, and BrainStorm continues to await FDA approval for the expansion of its ALS development to the U.S. The company entered a Memorandum of Understanding with the University of Massachusetts Medical School and Massachusetts General Hospital to begin its ALS human clinical trials at the institutions.

Don’t Miss: Apple’s Phantom iPhone Has a Ton of Buyers.

Albemarle Corp. (NYSE:ALB) was removed from Citigroup’s Top Picks Live list due to slower end market demand in electronics. The firm maintains its Buy rating and $69 price target on the shares.

NRG Energy, Inc.’s (NYSE:NRG) acquisition of GenOn Energy (NYSE:GEN) is believed by Wunderlich to be done at an attractive price, therefore representing a positive for shares. The firm mentions that NRG Energy’s preliminary Q2 EBITDA exceeded expectations. Wunderluch maintains its Buy rating and $23 price target on the stock.

Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) price target was raised by JPMorgan after FDA approval of Krypolis, and the firm states that it would still be a buyer of the stock despite the recent rally.

MDC Holdings Inc. (NYSE:MDC): According to Goldman, Homebuilders group is at the beginning of its long term positive trend, and increasing U.S. home prices will push housing starts. The firm recommends buying shares on pullbacks adding M.D.C. Holdings (NYSE:MDC) to its Conviction Buy List, upgrading KB Home (NYSE:KBH) to Buy from Neutral, raising Ryland Group (NYSE:RYL) to Neutral from Sell, and downgrading NVR (NYSE:NVR) to Sell from Neutral.

Don’t Miss: The Dow is NOT Lovin’ McDonald’s Right Now.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.